NCT06675214View on ClinicalTrials.gov

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

PHASE3RecruitingINTERVENTIONAL
Enrollment

586

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2030

Conditions
Nasopharyngeal CarcinomaDe-escalation Therapy
Interventions
DRUG

Full course of PD-1/PD-L1 blockades

a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.

DRUG

Cisplatin-based induction chemotherapy

Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.

RADIATION

Standard-dose IMRT

GTVnx/nd:69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82y CTV2: 54.12Gy/33Fr/1.64Gy

RADIATION

Gradient Fractionated IMRT

GTVresidue: 68Gy/30Fr/2.27Gy GTVmcr: 60Gy/30F/2Gy CTV1:54Gy/30F/1.8Gy CTV2: 48GY/30F/1.60Gy

DRUG

Concurrent Chemotherapy

Cisplatin 100mg/m2 every 3 weeks for 2 cycles

Trial Locations (1)

519000

RECRUITING

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai

All Listed Sponsors
lead

Sun Yat-sen University

OTHER